INCY News and Press, Incyte Corporation From 07/17/22

Four new VBR buy signals are discussed. I have become more cautious on the U.S. stock market's immediate direction, as the Federal Reserve continues to drain liquidity. When Wall Street turns bullish again, we should see an uptick in the number of companies to buy weekly, and much...

ARK Invest’s 13F portfolio value decreased from $23.96B to $16.91B this quarter. Coinbase Global, Roku, Shopify, and Ginkgo Bioworks were increased while decreasing Spotify, Ionis Pharma, Vertex Pharma, and Sea Limited. The top three positions are Tesla, Zoom Video, and Rok...

Cowen has initiated CTI Biopharma ( NASDAQ: CTIC ) with an outperform rating citing the growth potential of Vonjo (pacritinib), which was approved in February for thrombocytopenic myelofibrosis. Shares are up 14% in Thursday afternoon trading. The firm has a $10 pr...

This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. From 1/2/2016 to date investing in all 50 stocks, equally weighted, would have produced a total return of 69.6%, an...

Baker Brothers’ 13F portfolio value decreased from $20.55B to $17.40B this quarter. Horizon Therapeutics was increased while decreasing Legend Biotech. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to almost 68% of the portfolio. ...

The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte (INCY) Presents at the 27th Congress of the European Hematology Association (EHA) - Slideshow

In spite of half of our FMP's four building blocks trading in distress-mode, the portfolio/investment strategy is working just fine. Although stocks are no longer expensive, the economy is looking so fragile, posing a great deal of risk for further decline. This year's lead invest...

Incyte's 1Q 2022 results look solid. Jakafi keeps good revenue growth. Lower gross/net discount in 2H could boost Opzelura net revenue growth. The next driver could be the approval of ruxolitinib for the treatment of vitiligo (expected in the US by July 18, in Europe by the end of...

Bulls are trying to battle back in the stock market today. While broader markets continue licking their wounds, those trading penny stocks are having just another day at the office. Why’s that? It doesn’t seem to matter if there’s a bear market, bull market, or sideways...

FDA Approves Lilly and Incyte's OLUMIANT® (baricitinib) As First and Only Systemic Medicine for Adults with Severe Alopecia Areata PR Newswire INDIANAPOLIS , June 13, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced t...